TGFB1 and neoplasm: Using a nanoparticle formulation of siRNAs (targeting TGF-β and COX2) at 2 mg/kg IV BIW in a syngeneic orthotopic liver cancer model, we demonstrate rapid reduction of the tumor over the dosing period (six doses BIW; Figure 3C).